Innate Pharma (IPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Innate Pharma (IPH) has a cash flow conversion efficiency ratio of 0.995x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-21.59 Million ≈ $-25.24 Million USD) by net assets (€-21.70 Million ≈ $-25.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IPH market cap overview for the company's overall valuation and market capitalisation.
Innate Pharma - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Innate Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Innate Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innate Pharma ranked by their cash flow conversion efficiency. Explore Innate Pharma cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alkim Kagit Sanayi ve Ticaret AS
IS:ALKA
|
1.752x |
|
Luxchem Corporation Bhd
KLSE:5143
|
-0.001x |
|
Nordhealth AS
OL:NORDH
|
-0.008x |
|
Sunspring Metal Corp
TW:2062
|
0.035x |
|
Tirathai Public Company Limited
BK:TRT
|
0.287x |
|
RheinLand Holding AG
DU:RLV
|
N/A |
|
Daechang Forgi
KO:015230
|
-0.004x |
|
Mosa Industrial Corp
TW:4564
|
0.027x |
Annual Cash Flow Conversion Efficiency for Innate Pharma (2005–2025)
The table below shows the annual cash flow conversion efficiency of Innate Pharma from 2005 to 2025. View IPH share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-21.70 Million ≈ $-25.37 Million |
€-52.76 Million ≈ $-61.68 Million |
2.431x | +411.38% |
| 2024-12-31 | €8.83 Million ≈ $10.33 Million |
€-6.90 Million ≈ $-8.06 Million |
-0.781x | -24.44% |
| 2023-12-31 | €51.90 Million ≈ $60.68 Million |
€-32.56 Million ≈ $-38.06 Million |
-0.627x | -77.35% |
| 2022-12-31 | €54.15 Million ≈ $63.31 Million |
€-19.15 Million ≈ $-22.39 Million |
-0.354x | +34.99% |
| 2021-12-31 | €107.44 Million ≈ $125.61 Million |
€-58.46 Million ≈ $-68.34 Million |
-0.544x | -63.81% |
| 2020-12-31 | €155.97 Million ≈ $182.35 Million |
€-51.81 Million ≈ $-60.57 Million |
-0.332x | -306.78% |
| 2019-12-31 | €217.42 Million ≈ $254.18 Million |
€34.92 Million ≈ $40.83 Million |
0.161x | +182.58% |
| 2018-12-31 | €167.24 Million ≈ $195.52 Million |
€-32.53 Million ≈ $-38.03 Million |
-0.195x | +65.21% |
| 2017-12-31 | €85.96 Million ≈ $100.49 Million |
€-48.06 Million ≈ $-56.19 Million |
-0.559x | -30.74% |
| 2016-12-31 | €86.17 Million ≈ $100.74 Million |
€-36.85 Million ≈ $-43.08 Million |
-0.428x | -114.82% |
| 2015-12-31 | €72.07 Million ≈ $84.25 Million |
€207.91 Million ≈ $243.07 Million |
2.885x | +1287.24% |
| 2014-12-31 | €74.63 Million ≈ $87.25 Million |
€-18.13 Million ≈ $-21.20 Million |
-0.243x | +10.74% |
| 2013-12-31 | €40.29 Million ≈ $47.10 Million |
€-10.97 Million ≈ $-12.82 Million |
-0.272x | +39.28% |
| 2012-12-31 | €23.36 Million ≈ $27.31 Million |
€-10.47 Million ≈ $-12.25 Million |
-0.448x | -191.92% |
| 2011-12-31 | €26.62 Million ≈ $31.13 Million |
€12.99 Million ≈ $15.18 Million |
0.488x | +221.55% |
| 2010-12-31 | €33.52 Million ≈ $39.18 Million |
€-13.45 Million ≈ $-15.72 Million |
-0.401x | -218.54% |
| 2009-12-31 | €47.12 Million ≈ $55.09 Million |
€-5.94 Million ≈ $-6.94 Million |
-0.126x | +64.67% |
| 2008-12-31 | €41.34 Million ≈ $48.33 Million |
€-14.74 Million ≈ $-17.23 Million |
-0.357x | -90.56% |
| 2007-12-31 | €49.61 Million ≈ $57.99 Million |
€-9.28 Million ≈ $-10.85 Million |
-0.187x | -3029.85% |
| 2006-12-31 | €56.37 Million ≈ $65.90 Million |
€360.00K ≈ $420.88K |
0.006x | +101.77% |
| 2005-12-31 | €20.07 Million ≈ $23.46 Million |
€-7.25 Million ≈ $-8.47 Million |
-0.361x | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more